Skip to main content
SpringerLink
Log in

Pamidronat in der Behandlung der tumorassoziierten Hypercalcämie

Treatment of cancer associated-hypercalcemia with pamidronate

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

After a 48-hour rehydration period 28 of 31 patients with cancer-associated hypercalcemia (serum calcium ≥2.8 mmol/1) were treated intravenously with the bisphosphonate pamidronate. In three patients fluid repletion with 0.9% saline solution had already normalized serum calcium levels. Pamidronate was given in a single infusion on day 0, the dose of pamidronate adapted to the severity of hypercalcemia. If the serum calcium concentration was ≥2.8 mmol/1 on day 3, application of pamidronate was repeated. In all patients normocalcemia was restored; mean serum calcium decreased from 3.2±0.35 on day 0 to 2.15±0.32 on day 12. Hypercalcemia recurred in 11 patients, seven of these underwent pamidronate treatment according to the same therapeutical regimen. Normal calcium levels were attained in five cases. Side effects were of minor gravity:brief hyperthermia occurred in four patients and transient, asymptomatic hypocalcemia was noticed in nine cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

PTHrP:

Parathormon ähnliches Peptid

Literatur

  1. Blind E, Raue F, Zisterer A, Kohl B, Ziegler R (1990) Epidemiologie der Hypercalcämie. Dtsch Med Wschr 115:1739–1745

    Google Scholar 

  2. Body JJ, Borkowski A, Cleeren A, Bijvoet OLM (1986) Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 4:1177–1183

    Google Scholar 

  3. Bonjour JP, Philippe J, Guzelpa G, Bisetti A, Rizzoli R, Jung A, Rosini S, Kanis JA (1988) Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone 9:123–130

    Google Scholar 

  4. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Thesing CW, Bijvoet OLM (1986) Two modes of action of bisphosphonates on osteoclastic resorption of mineralized bone. Bone and Mineral 1:27–39

    Google Scholar 

  5. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, Stewart AF (1988) Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. New Engl J Med 319:556–563

    Google Scholar 

  6. Fleisch H (1989) Bisphosphonates:a new class of drugs in diseases of bone and calcium metabolism. In:Brunner KW, Fleisch H, Senn HJ (Hrsg) Bisphosphonates and tumor osteolysis. Springer, Berlin Heidelberg New York, S 1–28

    Google Scholar 

  7. Gurney H, Kefford R, Stuart-Harris R (1989) Renal phosphate threshold and response to pamidronate in humoral hypercalcemia of malignancy. Lancet II:241–244

    Google Scholar 

  8. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenar AJ, Vermeij P, Bijvoet OLM (1987) Paget's disease of bone:early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ 295:1301–1305

    Google Scholar 

  9. Harinck HIJ, Bijvoet OLM (1989) Clinical aspects of tumour-induced hypercalcemia of malignancy with APD. In:Burckhardt P (Hrsg) Disodium pamidronat (APD) in the treatment of malignancy related disorders. Huber, Bern Stuttgart Toronto, S 64–71

    Google Scholar 

  10. Harjung H, Fritze D (1990) Monotherapie mit Clodronat bei tumorinduzierter Hypercalcämie. Dtsch Med Wschr 115:48–52

    Google Scholar 

  11. Heath DA (1989) Hypercalcemia in malignancy. BMJ 298:1468–1469

    Google Scholar 

  12. Hosking DJ, Cowley A, Bucknall CA (1982) Rehydration in the treatment of severe hypercalcemia. Q J Med 200:473–481

    Google Scholar 

  13. Kanis JA, McCloskey EV, Paterson AHG (1990) Use of diphosphonates in hypercalcemia due to malignancy. Lancet I:170–171

    Google Scholar 

  14. Ladenson JH, Lewis JW, Boyd JC (1978) Failure of total calcium corrected for protein, albumin and pH to correctly assess free calcium status. J Clin Endocrin and Metab 46:986–993

    Google Scholar 

  15. Mangin M, Webb AC, Dreyer BE, Posillico JT, Ikeda K, Weir EC, Stewart AF, Bander NH, Milstone L, Barton DE, Francke U, Broadus AE (1988) Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA 85:597–601

    Google Scholar 

  16. Morton AR, Cantrill JA, Craig AE, Howell A, Davis M, Anderson DC (1988) Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcemia of malignancy. BMJ 296:811–814

    Google Scholar 

  17. Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall RE, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, Martin TJ (1987) Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 84:5048–5052

    Google Scholar 

  18. Ralston SH, Gardner MD, Dryhmburgh FJ, Jenkins AS, Cowan RA, Boyle IT (1985) Comparison of aminohydroxypropylidene diphosphonat, mithramycin, and corticosteroids/calcitonin in treatment of cancer associated hypercalcemia. Lancet II:907–910

    Google Scholar 

  19. Ralston SH, Alzard AA, Gallacher SJ, Gardner MD, Cowan RA, Boyle IT (1988) Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancerassociated hypercalcaemia. Q J Med 258:825–834

    Google Scholar 

  20. Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, Boyle IT (1989) Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet II:1180–1182

    Google Scholar 

  21. Ritch PS (1990) Treatment of cancer related hypercalcemia. Semin Oncol 17 [Suppl 4]:26–33

    Google Scholar 

  22. Scharla SH, Minne HW, Sattar P, Mende U, Blind E, Schmidt-Gayk H, Wüster C, Ho T, Ziegler R (1987) Therapie der Tumorhypercalciämie mit Clodronat. Dtsch Med Wschr 112:1121–1125

    Google Scholar 

  23. Scharla SH, Grauer A, Ziegler R (1991) Therapie des Morbus Paget mit dem Bisphosphonat (AHPrBP, früher APD) Klin Wochenschr 69:25–30

    Google Scholar 

  24. Thiebaud D, Jaeger P, Jacquet AF (1986) A single day treatment of tumor induced hypercalcemia by intravenous aminohydroxypropylidene bisphosphonate. J Bone Min Res 1:555–562

    Google Scholar 

  25. Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P (1988) Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 6:762–768

    Google Scholar 

  26. Thiebaud D, Jaeger P, Burckhardt P (1990) Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD):respective role of kidney and bone. J Bone Miner Res 5:221–226

    Google Scholar 

  27. Thomas M, Schneider W (1989) Differentialdiagnose und Therapie der tumorbedingten Hypercalcämien. Dtsch Med Wschr 114:1576–1581

    Google Scholar 

  28. Yakatan GJ, Wesley JP, Talbert RL, Floyd BF, Slough CL, Ampulski RS, Benedict JJ (1982) Clodronate kinetics and bioavailibility. Clin Pharmacol Ther 31:752–760

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. V. Medizinische Abteilung Krankenhaus der Stadt Wien Lainz, Österreich

    M. Pecherstorfer, S. Janisch, C. Marosi, C. Wogritsch, C. Bosse, W. Schratzberger, E. Gerber, A. Fortelny, R. Lenzhofer, H. Rainer, K. Klaushofer, G. Baumgartner & G. Schernthaner

  2. Zentrallaboratorium Krankenhaus der Stadt Wien Lainz, Österreich

    M. Pecherstorfer, S. Janisch, C. Marosi, C. Wogritsch, C. Bosse, W. Schratzberger, E. Gerber, A. Fortelny, R. Lenzhofer, H. Rainer, K. Klaushofer, G. Baumgartner & G. Schernthaner

  3. Universitätsklinik für Chemotherapie Wien, Österreich

    M. Pecherstorfer, S. Janisch, C. Marosi, C. Wogritsch, C. Bosse, W. Schratzberger, E. Gerber, A. Fortelny, R. Lenzhofer, H. Rainer, K. Klaushofer, G. Baumgartner & G. Schernthaner

  4. Interne Abteilung des Kardinal Schwarzenberg'schen Krankenhauses Schwarzach, Österreich

    M. Pecherstorfer, S. Janisch, C. Marosi, C. Wogritsch, C. Bosse, W. Schratzberger, E. Gerber, A. Fortelny, R. Lenzhofer, H. Rainer, K. Klaushofer, G. Baumgartner & G. Schernthaner

  5. IV. Medizinische Abteilung Hanusch-Krankenhaus Wien, Österreich

    M. Pecherstorfer, S. Janisch, C. Marosi, C. Wogritsch, C. Bosse, W. Schratzberger, E. Gerber, A. Fortelny, R. Lenzhofer, H. Rainer, K. Klaushofer, G. Baumgartner & G. Schernthaner

  6. I. Medizinische Abteilung Krankenhaus der Stadt Wien Rudolfstiftung, Österreich

    M. Pecherstorfer, S. Janisch, C. Marosi, C. Wogritsch, C. Bosse, W. Schratzberger, E. Gerber, A. Fortelny, R. Lenzhofer, H. Rainer, K. Klaushofer, G. Baumgartner & G. Schernthaner

Authors
  1. M. Pecherstorfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Janisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Marosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Wogritsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Bosse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Schratzberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Fortelny
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Lenzhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H. Rainer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K. Klaushofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G. Baumgartner
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G. Schernthaner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pecherstorfer, M., Janisch, S., Marosi, C. et al. Pamidronat in der Behandlung der tumorassoziierten Hypercalcämie. Klin Wochenschr 69, 690–695 (1991). https://doi.org/10.1007/BF01649438

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01649438

Key words

Search

Navigation